GLP-1 And AI Care Platform Will Support Powerful Long Term Chronic Condition Tailwinds

Catalysts

About Omada Health

Omada Health provides virtual, behavior change focused programs that support people with chronic conditions such as obesity, diabetes, hypertension and musculoskeletal issues.

What are the underlying business or industry changes driving this perspective?

• Growing employer and health plan focus on obesity and cardiometabolic conditions is feeding interest in Omada's GLP-1 Care Track and broader suite, which can support member growth and recurring revenue as more buyers look for comprehensive chronic care solutions.
• The planned introduction of GLP-1 prescribing within the existing care track gives Omada a fuller role across the medication life cycle. Management expects this to carry incremental pricing on top of current chronic condition fees and it could be supportive of revenue and gross margin.
• Expansion of AI driven tools like OmadaSpark and Meal Map is already linked internally to higher engagement and more consistent tracking. This can help keep members active in programs and support per member revenue and lifetime value.
• Omada's single multi-condition platform, sold by one sales force and distributed through large channel partners and PBMs, is helping more customers adopt multiple programs at once. This can support operating leverage, improve net margins and contribute to positive adjusted EBITDA.
• A growing body of peer reviewed evidence, including cost savings in virtual MSK care and weight maintenance after GLP-1 discontinuation, is strengthening Omada's clinical and economic value case with payers. This can support pricing power, contract wins and earnings over time.

Assumptions

This narrative explores a more optimistic perspective on Omada Health compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Omada Health's revenue will grow by 26.6% annually over the next 3 years.
• The bullish analysts are not forecasting that Omada Health will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Omada Health's profit margin will increase from -11.3% to the average US Healthcare industry of 5.5% in 3 years.
• If Omada Health's profit margin were to converge on the industry average, you could expect earnings to reach $25.7 million (and earnings per share of $0.36) by about January 2029, up from $-26.2 million today.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 111.5x on those 2029 earnings, up from -33.2x today. This future PE is greater than the current PE for the US Healthcare industry at 23.3x.
• The bullish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.96%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Omada Health is still reporting a net loss, with GAAP net loss at $3 million in Q3 2025 and management not yet at its long term adjusted EBITDA goal of 20% plus. If operating expenses tied to GLP-1 prescribing, AI tools and product build out grow faster than revenue over several years, the path to sustained profitability could stall, which would pressure earnings and net margins.
• The company is concentrating heavily on GLP-1 related offerings, including prescribing and life cycle support, at the same time that employers and health plans are rethinking whether and how to cover these drugs. If long term buyer policies shift away from GLP-1 coverage or toward lower cost point solutions, demand for Omada’s GLP-1 Care Track could weaken, which would affect member growth and revenue.
• Omada’s model depends on employers, health plans and PBMs paying recurring membership fees based partly on engagement. If engagement and retention trends in later cohorts do not hold up over time or competitors offer more attractive digital and human coaching options, member churn could rise and lower per member revenue and total revenue.
• The push into prescribing and broader AI driven tools requires investment in engineering, product, sales and marketing through at least 2026. If these projects encounter delays, regulatory hurdles or weaker customer uptake than management expects, the company could see higher operating costs without matching revenue contribution, which would compress gross margin and net margins.
• Omada’s growth is tied to large channel partners, consultants and B2B2C arrangements. If any major partner underperforms, changes priorities or promotes competing solutions in multi condition care over the long term, Omada could see slower member additions and less upsell into multiple programs, which would weigh on revenue growth and limit operating leverage.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Omada Health is $33.0, which represents up to two standard deviations above the consensus price target of $28.2. This valuation is based on what can be assumed as the expectations of Omada Health's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $33.0, and the most bearish reporting a price target of just $22.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $471.1 million, earnings will come to $25.7 million, and it would be trading on a PE ratio of 111.5x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $15.01, the analyst price target of $33.0 is 54.5% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.